TFA Therapeutics (RAJAF) EPS (Basic) (2020 - 2023)

TFA Therapeutics has reported EPS (Basic) for 4 years, with the latest figure at $0.0 in Q4 2023.

• On a quarterly basis, EPS (Basic) rose 115.84% year-over-year to $0.0 in Q4 2023; TTM through Dec 2023 was -$0.01, a N/A change from a year earlier, with the FY2021 full-year figure at $0.0, up 100.01% from the prior year.
• EPS (Basic) was $0.0 for Q4 2023 at TFA Therapeutics, up from -$0.0 in the prior quarter.
• The five-year high for EPS (Basic) was $0.0 in Q4 2023, with the low at -$0.0 in Q4 2021.
• Average EPS (Basic) over 4 years is -$0.0, with a median of -$0.0 recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: EPS (Basic) plunged 2657.69% in 2021, then surged 115.84% in 2023.
• Over 4 years, EPS (Basic) stood at -$0.0 in 2020, then slumped by 2657.69% to -$0.0 in 2021, then grew by 11.9% to -$0.0 in 2022, then soared by 115.84% to $0.0 in 2023.
• The last three EPS (Basic) figures came in at $0.0 (Q4 2023), -$0.0 (Q4 2022), and -$0.0 (Q4 2021), per Business Quant data.